This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval
Grail’s Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.
Source：MarketWatch
友情提醒：请广大读者理性看待市场信息，切实提高风险意识。站内所有内容仅系市场信息或相关方观点，不构成任何形式投资建议。